Detailed Information
Cited 28 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.
- Authors
- Modi, S[Modi, Shanu]; Jacot, W[Jacot, William]; Yamashita, T[Yamashita, Toshinari]; Sohn, J[Sohn, Joohyuk]; Vidal, M[Vidal, Maria]; Tokunaga, E[Tokunaga, Eriko]; Tsurutani, J[Tsurutani, Junji]; Ueno, NT[Ueno, Naoto T.]; Chae, YS[Chae, Yee Soo]; Lee, KS[Lee, Keun Seok]; Niikura, N[Niikura, Naoki]; Park, YH[Park, Yeon Hee]; Wang, XJ[Wang, Xiaojia]; Xu, BH[Xu, Binghe]; Gambhire, D[Gambhire, Dhiraj]; Yung, L[Yung, Lotus]; Meinhardt, G[Meinhardt, Gerold]; Wang, YB[Wang, Yibin]; Harbeck, N[Harbeck, Nadia]; Cameron, DA[Cameron, David A.]
- Issue Date
- 10-Jun-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.17
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 17
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.